Skip to content

Author

Ananthan Sadagopan

We have 3 of 44 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

BCL-XL dependence is a subtype agnostic actionable feature of difficult-to-treat kidney cancers

BCL-X L is a BCL-2 family anti-apoptotic protein that functions as a targetable dependency in clear cell Renal Cell Carcinoma (ccRCC), the most common form of adult kidney cancer. However, the mechanisms driving this dependence are unclear. Moreover, although significant strides have been made in managing ccRCC,...

Tupa Basuroy, Treg M. Grubb, Ananthan Sadagopan et al. · 0 citations
Aug 2026

Interpretable Prediction of Ligand-Protein Binding without Protein Structural Information.

Ligand-protein binding prediction remains a central challenge, yet the contribution of ligand-side information to performance is unclear and ligand-only models as interpretable screening tools are established and used as a baseline for assessing the added value of protein representations.

Ananthan Sadagopan, Anurag Sodhi, William J. Gibson · 0 citations
Jul 2026

Abstract PR006: Target discovery in rare cancers enabled by transcriptome-based virtual CRISPR screening

It is demonstrated that machine learning applied to transcriptomic data can uncover novel cancer vulnerabilities and actionable targets in individual tumors, even in the absence of functional screening, which may represent a scalable approach to advance precision oncology in rare and/or under-characterized cancer types...

Ananthan Sadagopan, Bingchen Li, Jiao Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.